FDA Says Take Note: Document Supplement GMP Corrections
This article was originally published in The Rose Sheet
FDA's latest supplement GMP warnings once again demonstrate the importance of appropriate documentation during manufacturing and in responding to questions from agency inspectors.
You may also be interested in...
Warnings from FDA's Office of Regulatory Affairs make clear that failing to document compliance with each GMP requirement renders those parts of the process noncompliant. Warning letters posted March 22 also include FDA's latest enforcement against firms marketing bulk caffeine.
Without a guidance for requesting fee reductions, FDA will not bill firms for re-inspections of facilities found non-compliant with manufacturing regulations or for costs linked to a firm failing to comply with a recall order.